Previous Close | 0.2445 |
Open | 0.2427 |
Bid | 0.2400 x 1100 |
Ask | 0.2570 x 1800 |
Day's Range | 0.2400 - 0.2596 |
52 Week Range | 0.1720 - 2.0800 |
Volume | |
Avg. Volume | 278,415 |
Market Cap | 8.309M |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0440 |
Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for NBSE
NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues). For this research, the Healthcare Company will evaluate NeuBase’s PATrOL™ technology for three monogenic genetic di